Journal ArticleDOI
Fluorine-containing drugs approved by the FDA in 2019
Haibo Mei,Attila Márió Remete,Yupiao Zou,Hiroki Moriwaki,Santos Fustero,Loránd Kiss,Vadim A. Soloshonok,Vadim A. Soloshonok,Jianlin Han +8 more
Reads0
Chats0
TLDR
Eleven new fluorine-containing FDA-approved drugs have been profiled and details of their discovery and preparation are discussed, including four examples of aromatic fluorine, three aromatic CF3 group, three aliphatic CF3 and one compound with aromaticCF3O group.About:
This article is published in Chinese Chemical Letters.The article was published on 2020-09-01. It has received 134 citations till now.read more
Citations
More filters
Journal ArticleDOI
U.S. FDA Approved Drugs from 2015-June 2020: A Perspective
Priyadeep Bhutani,Priyadeep Bhutani,Gaurav Joshi,Nivethitha Raja,Namrata Bachhav,Prabhakar Rajanna,Hemant Bhutani,Atish T. Paul,Raj Kumar +8 more
TL;DR: In this paper, the authors report compilation and analysis of 245 drugs, including small and macromolecules approved by the U.S. FDA from 2015 until June 2020, and they report that nearly 29% of the drugs were approved for the treatment of various types of cancers.
Journal ArticleDOI
Next generation organofluorine containing blockbuster drugs
Jianlin Han,Attila Márió Remete,Luca S. Dobson,Loránd Kiss,Kunisuke Izawa,Hiroki Moriwaki,Vadim A. Soloshonok,Vadim A. Soloshonok,David O'Hagan +8 more
TL;DR: This Review highlights a selection of the most successful organo-fluorine drugs, that have achieved blockbuster status, namely, sitagliptin (diabetes), sofosbuvir (hepatitis C), emtricitabine (HIV), glecaprevir/pibrentasvir ( hepatitisC), elvitegravir (Hiv), dolutegravirs (H HIV), bictegravIR (H IV),
Journal ArticleDOI
Chemical Aspects of Human and Environmental Overload with Fluorine
Jianlin Han,Loránd Kiss,Haibo Mei,Attila Márió Remete,Maja Ponikvar-Svet,Daniel M. Sedgwick,Raquel Román,Santos Fustero,Hiroki Moriwaki,Vadim A. Soloshonok,Vadim A. Soloshonok +10 more
TL;DR: A comprehensive and critical review of the effects of fluoride ions and organofluorine compounds (mainly pharmaceuticals and agrochemicals) on human health and the environment is presented in this article.
Journal ArticleDOI
Fluorinated Pyrazoles: From Synthesis to Applications.
TL;DR: Analysis of novel synthetic approaches to fluorinated pyrazoles that appeared in recent years is performed, with a particular emphasis on a detailed consideration of reaction mechanisms.
Journal ArticleDOI
Biological Utility of Fluorinated Compounds: from Materials Design to Molecular Imaging, Therapeutics and Environmental Remediation
TL;DR: A review of fluorine-fluorine-containing materials in imaging, therapeutics, and environmental applications is presented in this article, focusing on the design and utility of C-F containing materials.
References
More filters
Journal ArticleDOI
5-Fluorouracil: mechanisms of action and clinical strategies
TL;DR: This work has shown that novel genes identified in DNA microarray profiling have the potential to identify novel genes that are involved in mediating resistance to 5-FU, and these genes might prove to be therapeutically valuable as new targets for chemotherapy, or as predictive biomarkers of response to5-FU-based chemotherapy.
Journal ArticleDOI
Fluorine in pharmaceutical industry: fluorine-containing drugs introduced to the market in the last decade (2001-2011).
Jiang Wang,María Sánchez-Roselló,José Luis Aceña,Carlos del Pozo,Alexander E. Sorochinsky,Alexander E. Sorochinsky,Alexander E. Sorochinsky,Santos Fustero,Vadim A. Soloshonok,Vadim A. Soloshonok,Hong Liu +10 more
TL;DR: Introduced to the Market in the Last Decade (2001−2011) Jiang Wang,† María Sańchez-Rosello,́‡,§ Jose ́ Luis Aceña, Carlos del Pozo,‡ and Hong Liu.
Journal ArticleDOI
Synopsis of some recent tactical application of bioisosteres in drug design.
TL;DR: In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compound optimization and the long-term success of drug candidates.
Journal ArticleDOI
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
Yu Zhou,Jiang Wang,Zhanni Gu,Shuni Wang,Wei Zhu,José Luis Aceña,Vadim A. Soloshonok,Kunisuke Izawa,Hong Liu +8 more
TL;DR: Compounds Currently in Phase II−III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas is presented.